These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34391066)

  • 21. Development and multi-center clinical trials of an up-converting phosphor technology-based point-of-care (UPT-POCT) assay for rapid COVID-19 diagnosis and prediction of protective effects.
    Zhang P; Li B; Wang Y; Min W; Wang X; Zhou Y; Li Z; Zhao Y; Zhang H; Jiang M; Zheng H; Yang C; Zhang W; Zuo L; Gao Q; Yang Z; Li Y; Feng T; Lin C; Hu Q; Song T; Yang R
    BMC Microbiol; 2022 Feb; 22(1):42. PubMed ID: 35114938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
    Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
    PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies.
    Li J; Liu B; Tang X; Wu Z; Lu J; Liang C; Hou S; Zhang L; Li T; Zhao W; Fu Y; Ke Y; Li C
    Int J Infect Dis; 2022 Aug; 121():58-65. PubMed ID: 35483554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT).
    Meyer B; Reimerink J; Torriani G; Brouwer F; Godeke GJ; Yerly S; Hoogerwerf M; Vuilleumier N; Kaiser L; Eckerle I; Reusken C
    Emerg Microbes Infect; 2020 Dec; 9(1):2394-2403. PubMed ID: 33043818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
    Gillot C; Favresse J; Maloteau V; Dogné JM; Douxfils J
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories.
    Fischer B; Lichtenberg C; Müller L; Timm J; Fischer J; Knabbe C
    J Clin Virol; 2021 Nov; 144():104984. PubMed ID: 34563863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2.
    Hofmann N; Grossegesse M; Neumann M; Schaade L; Nitsche A
    Sci Rep; 2022 Mar; 12(1):3549. PubMed ID: 35241780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera].
    Astakhova EA; Byazrova MG; Yusubalieva GM; Larichev VF; Baklaushev VP; Filatov AV
    Mol Biol (Mosk); 2022; 56(6):1095-1103. PubMed ID: 36475494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
    Ismail A; Shurrab FM; Al-Jighefee HT; Al-Sadeq DW; Qotba H; Al-Shaar IA; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Front Biosci (Landmark Ed); 2021 Jul; 26(7):198-206. PubMed ID: 34340267
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
    Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
    Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2.
    Watanabe Y; Matsuba I; Watanabe K; Kunishima T; Takechi Y; Takuma T; Araki Y; Hirotsu N; Sakai H; Oikawa R; Danno H; Fukuda M; Futagami S; Wada K; Yamamoto H; Itoh F; Oda I; Hatori Y; Degawa H
    J Clin Lab Anal; 2022 Jul; 36(7):e24545. PubMed ID: 35678628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests.
    Habermann E; Frommert LM; Ghannam K; Nguyen My L; Gieselmann L; Tober-Lau P; Klotsche J; Arumahandi de Silva AN; Ten Hagen A; Zernicke J; Kurth F; Sander LE; Klein F; Burmester GR; Biesen R; Albach FN
    J Clin Virol; 2023 Aug; 165():105518. PubMed ID: 37354690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects.
    Saker K; Pozzetto B; Escuret V; Pitiot V; Massardier-Pilonchéry A; Mokdad B; Langlois-Jacques C; Rabilloud M; Alfaiate D; Guibert N; Fassier JB; Bal A; Trouillet-Assant S; Trabaud MA
    J Clin Virol; 2022 Jul; 152():105169. PubMed ID: 35568003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
    von Rhein C; Scholz T; Henss L; Kronstein-Wiedemann R; Schwarz T; Rodionov RN; Corman VM; Tonn T; Schnierle BS
    J Virol Methods; 2021 Feb; 288():114031. PubMed ID: 33275926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test.
    Lynch KL; Zhou S; Kaul R; Walker R; Wu AH
    Clin Chem; 2022 May; 68(5):702-712. PubMed ID: 35018416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients.
    Lerdsamran H; Anusorntanawat R; Sangsiriwut K; Sawadpongpan S; Prasertsopon J; Thinpan N; Intalapaporn P; Techasuwanna R; Okada P; Puthavathana P
    PLoS One; 2024; 19(4):e0298033. PubMed ID: 38626137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
    Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
    Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia.
    Chen W; Zhang J; Qin X; Wang W; Xu M; Wang LF; Xu C; Tang S; Liu P; Zhang L; Liu X; Zhang Y; Yi C; Hu Z; Yi Y
    Biomed Pharmacother; 2020 Oct; 130():110629. PubMed ID: 33406577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance.
    Nicholson S; Karapanagiotidis T; Khvorov A; Douros C; Mordant F; Bond K; Druce J; Williamson DA; Purcell D; Lewin SR; Sullivan S; Subbarao K; Catton M
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab239. PubMed ID: 34258311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.